{"sourcedb":"DevicePMAs@therightstef","sourceid":"P000011_S003","text":"Approval for:  1) the biodivysio(tm) sv otw in 10 mm, 15 mm and 18 mm stent lengths and 2.0 mm and 2.5 mm diameters.  The device, as modified, will be marketed under the trade name biodivysio(tm) sv otw and is indicated for \"improving coronary luminal diameter in subjects experiencing abrupt closure or threatened abrupt vessel closure following percutaneous revascularization of de novo or non in-stent restenotic native coronary artery lesions (length of lesion and/or dissection \u003C=25 mm) with a reference vessel diameter ranging from \u003E=2.0 mm to \u003C=3.0 mm by visual estimate.  Long-term outcome (beyond 6 months) for this implant is unknown at present.\"  2) the biodivysio(tm) as otw in 11 mm and 15 mm stent lengths and 3.0 mm, 3.5 mm and 4.0 mm diameters.  The device, as modified, will be marketed under the trade name biodivysio(tm) as otw and is indicated for improving coronary luminal diameter in the following: a) subjects with symptomatic ischemic heart disease due to de novo native coronary artery lesions (length \u003C=25 mm) with a reference vessel diameter ranging from \u003E=3.0 mm to 4.0 mm;  b) subjects experiencing aburpt closure or threatened abrupt vessel closure following percutaneous revascularization of de novo or non in-stent restenotic native coronary artery lesions (length of lesion and/or dissection \u003C=25 mm) with reference vessel diameter ranging from \u003E=3.0 mm to \u003C=4.0 mm by visual estimation.  Long term outcome (beyond 6 months) for these permanent implants are unknown at present.","project":"consensus_PMA_Age_Indications"}